Mylan
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.
| Mylan N.V. | |
| Formerly | Milan |
| Company type | Public (under Dutch law) |
| Industry | Pharmaceuticals |
| Founded | 1961 in White Sulphur Springs, West Virginia, United States |
| Founders | Milan Puskar Don Panoz |
| Defunct | November 16, 2020 |
| Fate | merged with Upjohn to form Viatris |
| Successor | Viatris |
| Headquarters | , |
| Products | Generic and specialty pharmaceuticals and active pharmaceutical ingredients |
| Divisions | see Operations |
| Website | www |
In 2007, the company acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients (APIs) for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, the company grew from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world.
Mylan went public on the OTC market in February 1973. It was listed on the NASDAQ, and its shares were a component of the NASDAQ Biotechnology and the S&P 500 indices.
The company was founded in 1961 and developed and produced medicines for a wide range of medical disciplines, including oncology, anaphylaxis, antiretrovirals, cardiovascular, respiratory, dermatology, immunology, anesthesia and pain management, infectious disease, gastroenterology, diabetology/endocrinology, and women's healthcare.